Most Cited Article – Investigating the Impact of Cognitive-behavioral Stress Management on Adjustment among Females with Breast Cancer

Author(s):Farkhondeh Jamshidi Arezoo Shayan and Mahtab Sattari *

Volume 18, Issue 4, 2022

Published on: 19 January, 2022

Article ID: e201221199150

Pages: 10

DOI: 10.2174/1573404818666211220105207

Abstract

Background and aim: This study aimed to investigate the effect of cognitive-behavioral stress management (CBSM) on adjustment among females with breast cancer.

Materials and Methods: This randomized clinical trial study was conducted on 104 women with breast cancer who visited Hamedan Imam Khomeini Clinic between Feb 3 and Oct 26, 2016, and met the inclusion criteria. The inclusion criteria included being 20 to 60 years old, being married, and having grade 1-3 breast cancer with a history of recent surgery. The subjects were randomly assigned to two groups of 52 subjects, using a permuted block size of 4. The intervention group participated in 4 sessions of CBSM, each 90 minutes long, for a duration of 4 weeks. Data collection was done using a demographic information questionnaire and Bell adjustment questionnaire. The statistical analyst remained unaware of the intervention assignment. Data analysis was done using descriptive statistics, paired t-test, and repeated measures ANOVA.

Results: There was a significant difference in the mean scores of the total adjustment (P = 0,0001) between the two groups after the intervention. Each variable was calculated three times, prior to the intervention, immediately after and 2 weeks after the intervention. Regardless of the time of measurement, there was a significant difference in the mean score of total adjustment between the two groups (P = 0.0001).

Conclusion: The cognitive-behavioral stress management program improved the adjustment immediately and 2 weeks after the intervention was done among women with breast cancer. This method can be implemented as a complementary approach along with medical therapies provided by oncology centers. Read now: https://bit.ly/3ey59iO

Testimonial By Nasim Sarrami

Read what our Authors have to say about publishing in our Journal

Nasim Sarrami

 

Journal Name: Anti-Cancer Agents In Medicinal Chemistry

Contributed Article:  LHRH Targeted Chonderosomes Of Mitomycin C In Breast Cancer: An In Vitro/ In Vivo Study

Press Release | Frontiers in clinical drug research — Anti-cancer agents, now in its 5th edition

9789811405150-1

This eBook is authored by Dr. Ata-ur-Rahman, published on June 12, 2019.

For Further Details, Please visit https://ebooks.benthamscience.com/book/9789811405150/

 

Frontiers in Clinical Drug Research – Anti-Cancer Agents brings updated and critical information about developing clinical trials and research in anti-cancer research. Reviews in each volume are written by experts in medical oncology and clinical trials research and compile the latest information available on special topics of interest to oncology researchers.

The fifth volume of the series features reviews on biochemical inhibitors (second-generation protein kinase Inhibitors, histone deacetylase inhibitors, immune checkpoint inhibitors, EGFR Tyrosine Kinase inhibitors, non-coding RNAs), apoptosis, and physical exercise therapy for cancer patients undergoing chemotherapy. The treatment strategies in this volume cover neoplasms such as acute myeloid leukemia, gastrointestinal cancer, breast cancer and lung cancer. Read full press release to find out more at: https://www.eurekalert.org/pub_releases/2019-06/bsp-fic062019.php

Press Release | Impact of a psycho-educational team in early breast cancer patients’ coping strategies

 

Cancer is a psychologically traumatic experience for affected individuals. Chemotherpautic medications can also be painful to the same patients. Researchers at Fondazione Poliambulanza, Brescia, Italy conducted a psycho-educational study on early stage breast cancer patients. The main objective of the study was to help women to cope with the physical emotional, and lifestyle changes after the diagnosis of breast cancer by evaluating the effect of group action on the participating women. A total of 97 women, participated in the study and were grouped into in 13 psycho-educational groups. All the groups consisted of female patients suffering from breast cancer with no recurrence or metastasis.

All the patients were evaluated using the Hospital Anxiety and Depression Scale (HADS) and the Body Image Scale (BIS). No significant effect on anxiety and body image was found by the researchers. They, however, noted a statistical difference between the results of the HADS depression test at T0 (first evaluation) and T1 (second evaluation) intervals. Read full press release to find out more at: https://www.eurekalert.org/pub_releases/2018-12/bsp-ioa122718.php

 

d3787968271aadf66b69e2f7e02571e2_XL

 

This article by Dr. Fausto Meriggi et al. is published in Reviews on Recent Clinical Trials, Volume 13, Issue 4, 2018. To obtain the article, please visit: http://www.eurekaselect.com/161134

 

Press Release | Fighting to Find Relief: A new study shows decrease in depression in cancer patients

 

A New Study Published by Bentham Science Shows Support Groups and Educational Resources Can Decrease Depression in Breast Cancer Patients

 

1 in 8 women in the US will be diagnosed with breast cancer in their lifetime.

In 2018 alone, an estimated 266,120 new cases of breast cancer were diagnosed nationwide. As the numbers of new cases grow, the support network of women who suffer from breast cancer grows. In their ever-increasing numbers, the many women diagnosed with this disease face an arduous physical and emotional journey on their road to recovery, and along the way, many suffer from depression, anxiety, and body image issues.

Regardless of the prevalence of body image issues, anxiety, and depression in women who are suffering from breast cancer, there aren’t a lot of resources available for those afflicted. A recent study suggests it’s time to right that wrong. The study, published by Bentham Science, focused on Dr. Fausto Meriggi and his team at Fondazione Poliambulanza di Brescia who studied the effects of psychotherapeutic and educational groups on depression, anxiety, and body image issues among women suffering from breast cancer.

big-004

This study was published in Reviews on Recent Clinical Trials, a journal published by Bentham Science.  Bentham Science continues their work in the Middle East and North Africa, bringing education materials and increased accessibility to the region.

 

Read full press release to find out more at: http://bit.ly/2E6ZBah

Press Release | Estrogen is a much more effective anticancer agent than antiestrogens

 

This article by Prof. Zsuzsanna Suba is published in Recent Patents on Anti-Cancer Drug Discovery, Volume 12, Issue 2, 2017

Antiestrogen treatment was introduced into breast cancer therapy based on the presumed carcinogenic capacity of endogenous estrogen hormones. In antiestrogen resistant breast cancers, increased expression and activity of estrogen receptors (ERs) is regarded as a survival technique, presuming that increased estrogen signaling is an absolutely proliferative stimulus. Unexpectedly, among certain circumstances, estrogen treatment is capable of inducing apoptotic death in tumors, even in antiestrogen resistant ones justifying the strong apoptotic capacity of estrogen. Analysis of the results of studies on both estrogen and antiestrogen treated tumors may clarify the associations among artificial ER blockade, compensatory restoration of ER signaling and the clinical behavior of cancers.

Inherited BRCA1/2 mutations may be regarded as pathologic models of defective estrogen signaling. In BRCA mutation carriers, the liganded activation of ERs is weak, while an increase in unliganded ER activation results in a more or less compensatory upregulation of ER signaling. Mutation carriers exhibit failure in their ovarian functions, while their risk for cancer is strongly increased (for breast cancer in particular). In cases carrying BRCA mutation, an increase in estrogen levels via either endogenous estrogen synthesis in pregnancy or exogenous estrogen administration via contraceptive use may reduce the risk of cancer development.

Estrogen activated ERs are the principal initiators and organizers of DNA stabilization. ERs work in an upregulative circuit with CYP19 aromatase enzyme and genome safeguarding proteins including BRCAs. The upregulative circuit ensures a strong DNA protection during the proliferation of healthy cells, whilst inducing apoptotic death in spontaneously initiated malignant cells in a Janus faced manner. By contrast, malignant cell proliferation exhibits a downregulative circuit between the low and/or defective expressions of ER and BRCA proteins. The malfunction of ER signaling is coupled with a damaged control of DNA replication resulting in an unrestrained proliferation of poorly differentiated tumor cells. In conclusion, in patients with cancer, estradiol induced upregulation of ER signaling may be an excellent means for the restoration of genome stabilizer machinery and for inducing apoptotic death in cancer cells.

Estrogen treatment upregulates the remnants of genome stabilizer machinery in breast cancer cell lines so as to induce an apoptotic death. Estrogen administration increases the expression and transcriptional activity of ERs in tumor cells, via both liganded and unliganded pathways. In patients, of all examined tumor markers, an increased expression of ERs in their breast cancer defines the prolonged survival. Moreover, the activation of ER-alpha at Ser 167 in tumors is indicative of longer disease free and overall survival in breast cancer patients.

Estrogen treatment induces ESR1 gene amplification resulting in higher expression levels of ERs in breast cancers. Patients exhibiting ESR1 gene amplification in their tumors, experience longer disease free survival than those without it.

Estradiol treatment mediates an increased expression of long non coding RNAs (lncRNAs) including HOTAIR in breast cancer cells. HOTAIR is capable of epigenetic gene modifications resulting in necessary activating mutations in the ESR1 gene. Patients with increased HOTAIR expression in their tumors were found to have lower risks for relapse and mortality than those showing low HOTAIR expression.

Estradiol treatment increases aromatase expression and activity in breast cancer cells in a dose dependent manner. Estradiol activated ERs strongly upregulate the estrogen synthesis of aromatase enzyme so as to increase estrogen signaling and to induce consequential DNA restoration and apoptotic death. Among breast cancer cases, a direct correlation was experienced between the aromatase activity of removed tumors and the patient’s survival time after surgery. Moreover, among young women with breast cancer, the absence of CYP19 aromatase activity in their surgically removed tumors carried a high risk for local cancer recurrence.

Estrogen treatment induces an upregulated expression of DNA safeguarding BRCA1 protein in breast cancer cell lines. In turn, it was found that the BRCA1 protein promotes ESR1 gene activation and transcriptionally upregulates ER-alpha expression in tumor cells. These correlations justify that ER-alpha and BRCA1 protein work in close partnership in the DNA stabilization process which provides apoptotic stimuli for breast cancer cells.

In conclusion, treatment with estrogen may strongly upregulate both estrogen signaling and DNA safeguarding in breast cancers promoting tumor responses. In antiestrogen responsive tumors, the blockade of liganded ER activation via either tamoxifen or aromatase inhibitor, provokes compensatory overexpression and hyperactivity of both ERs and aromatase enzyme via unliganded activations of partially blocked ERs. This compensatory activation of estrogen signaling may restore DNA stability promoting tumor responses. By contrast, in antiestrogen resistant tumors, a long term, exhaustive tamoxifen or aromatase inhibitor treatment induces a compensatory extreme upregulation of ER signaling; however, it may be insufficient to break through the near complete, artificially induced ER blockade. Antiestrogen resistant tumors exhibit a rapid growth in spite of the continuous administration of antiestrogens.

 

Browse the Article at: Activating Mutations of ESR1, BRCA1 and CYP19 Aromatase Genes Confer Tumor Response in Breast Cancers Treated with Antiestrogens

Article by Disease | Design, Synthesis, and Biological Evaluation of New Azole Derivatives as Potent Aromatase Inhibitors with Potential Effects against Breast Cancer

Bentham Oncology Collection | Oncology | Breast Cancer

 

Graphical Abstract:

Abstract:

Purpose: Some aromatase inhibitors are FDA-approved agents as first-line therapy in the treatment of endocrine-responsive breast cancer. In this study, we aimed to develop new azole derivatives with higher specificity and potency.

Methods: New aromatase inhibitors were designed by Molecular Operating Environment (MOE) software and synthesized in a one-step SN2 reaction. These compounds were characterized by melting point, 1H- and 13CNMR, elemental analysis and mass spectra. The in vitro and in vivo aromatase inhibition of these compounds was evaluated using the Estrone ELISA assay, and by measuring the inhibition of androstenedione-induced uterine hypertrophy. The selectivity of aromatase inhibition was investigated by the inhibition of ACTH stimulation on the plasma concentrations of aldosterone and cortisol.

Results: Docking simulations showed that four new azole derivatives could efficiently interact with enzyme active sites. The in vitro aromatase-inhibition assay showed that the compounds 1,3,5-tris(imidazol-1- ylmethyl)benzene (3b) and 1,3-Bis(imidazole-1- ylmethyl) benzene (3d) effectively inhibited aromatase, with IC50 values of 0.2 nM and 6.8 nM, respectively; these values were similar to known aromatase inhibitor letrozole (IC50 0.3 nM). The in vivo aromatase-inhibitory potency of compound 3b was similar to letrozole, although compound 3b acted more selectively.

Conclusion: This report introduced a new compound that can be considered as a new lead for further investigation to explore more-potent and more-selective aromatase inhibitors.

 

 

Read out more at: http://www.eurekaselect.com/node/159088/article

Article by Disease |Design, Synthesis and Anti-breast Cancer Activity of Some Novel Substituted Isoxazoles as Anti-breast Cancer Agent

Bentham Oncology Collection | Oncology | Breast Cancer

Graphical Abstract:

 

 

Abstract:

Methods: A novel series of isoxazole (S21-S30) derivatives were designed, synthesized and screened for their anticancer activity against estrogen receptor-positive MCF-7 and negative MDA-MB-435 breast cancer cell lines. The synthesized derivative has the ability to inhibit the growth of the human breast cancer cell line at low concentrations. In vivo anticancer activity was performed on virgin female sprague dawley rats.

Results: The result shows that compound S23 has more selectivity and marked estrogen modulator activity than the standard tamoxifen.

 

Open Access Articles – Oncolytic Virotherapy for Breast Cancer Treatment

Journal Name: Current Gene Therapy

Author(s): Samia M. O`Bryan, J. Michael Mathis*.

Abstract:

Breast cancer continues to be a leading cause of mortality among women. While at an early stage, localized breast cancer is easily treated; however, advanced stages of disease continue to carry a high mortality rate. The discrepancy in treatment success highlights that current treatments are insufficient to treat advanced-stage breast cancer. As new and improved treatments have been sought, one therapeutic approach has gained considerable attention. Oncolytic viruses are uniquely capable of targeting cancer cells through intrinsic or engineered means. They come in many forms, mainly from four major virus groups as defined by the Baltimore classification system. These vectors can target and kill cancer cells, and even stimulate immunotherapeutic effects in patients. This review discusses not only individual oncolytic viruses pursued in the context of breast cancer treatment but also the emergence of combination therapies with current or new therapies, which has become a particularly promising strategy for treatment of breast cancer. Overall, oncolytic virotherapy is a promising strategy for increased treatment efficacy for advanced breast cancer and consequently provides a unique platform for personalized treatments in patients.

For more details, please visit: http://www.eurekaselect.com/165254

EDITOR’S CHOICE ARTICLE – Arachidonic Acid Induces the Migration of MDA-MB-231 Cells by Activating Raft-associated Leukotriene B4 Receptors

Journal Name: Clinical Cancer Drugs

Author(s): Atasi De Chatterjee, Debarshi Roy, Priscilla Guevara, Rituraj Pal, Mahesh Narayan, Sukla Roychowdhury, Siddhartha Das*.

 

 

 

Graphical Abstract:

 

 

Abstract:

Background: The migration of tumor cells is critical in spreading cancers through the lymphatic nodes and circulatory systems. Although arachidonic acid (AA) and its soluble metabolites have been shown to induce the migration of breast and colon cancer cells, the mechanism by which it induces such migration has not been fully understood.

Objective: The effect of AA on migratory responses of the MDA-MB-231 cell line (a triple-negative breast cancer cell) was examined and compared with MCF-7 (estrogen-receptor positive) breast cancer cells to elucidate the mechanism of AA-induced migration.

Methods: Migrations of breast cancer cells were examined with the help of wound-healing assays. AA-induced eicosanoid synthesis was monitored by RP-HPLC. Cellular localizations of lipoxygenase and lipid rafts were assessed by immunoblot and confocal microscopy.

Results: AA treatment stimulated the synthesis of leukotriene B4 (LTB4) and HETE-8, but lowered the levels of prostaglandin E2 (PGE2), prostaglandin D2 (PGD2), and HETE-5 in MDA-MB-231 cells. Further analysis indicated that AA increased the expression of 5-lipoxygenase (5-LOX) in this cell line and inhibiting its expression by small molecule inhibitors lowered the production of LTB4 and reduced migration. In contrast, MCF-7 cells did not show any appreciable changes in eicosanoid synthesis, 5-LOX expression, or cellular migration.

Conclusion: Our results suggest that AA treatment activates the BLT1 receptor (present in membrane microdomains) and stimulates the synthesis of LTB4 production, which is likely to be associated with the migration of MDA-MB-231 cells.

 

 

For more details, please visit: http://www.eurekaselect.com/161381/article

%d bloggers like this: